Stay updated on Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.

Sign up to get notified when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the study record details of a clinical trial investigating the efficacy and safety of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for the treatment of early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.
    Difference
    0.0%
    Check dated 2024-06-06T14:37:20.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying the required health conditions and prior treatments for inclusion in the study. This change provides more specific information about the type of breast cancer and other health requirements needed for participation.
    Difference
    16%
    Check dated 2024-05-22T21:13:08.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2024-04-30T22:47:12.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.